Literature DB >> 10985475

Cytotoxic activity of several unrelated drugs on L1210 mouse leukemic cell sublines with P-glycoprotein (PGP) mediated multidrug resistance (MDR) phenotype. A QSAR study.

A Breier1, Z Drobná, P Docolomansky, M Barancik.   

Abstract

L1210/VCR-1 and L1210/VCR-2 cell lines are multidrug resistant (MDR) sublines obtained by adaptation of mouse leukemic cell line L1210 to vincristine and, the development of MDR in these cell lines has been found to be associated with an overexpression of P-glycoprotein (PGP). In the present work we studied the relationship between the structure of 15 cytotoxic active substances (drugs) and their cytotoxicities on L1210/VCR-1 and L1210/VCR-2 resistant cell lines. The resistance of these MDR cells to the respective drugs was expressed as the ratio of IC50 values obtained for resistant and sensitive cells. These values of resistance were correlated with the following physico-chemical constants of the test substances: binding energy, Ebind; total energy of the molecule, Esum; aromaticity, Kpi; molecular weight, Mw; acidobasic constant, pKa; partition coefficient in water/octanol two phase system, log(p). It has been found that according to the cytotoxic effects the tested drugs may be divided into three groups: (i) drugs with higher cytotoxicity to the resistant cell lines as to sensitive cells (collateral hypersensitivity); (ii) drugs exhibiting approximately similar effects on sensitive and resistant cell lines; (iii) drugs with weaker cytotoxicity to resistant cells than to sensitive cells. No direct correlations with any physico-chemical constant described above could be established for cell resistance to the drug studied. However, resistance values could be fitted by multiple exponential regression with all described physico-chemical constants implied as six independent variables. The latter procedure made us to conclude that the ability of a drug to be a substrate for PGP is connected with its fulfilling the following criteria: (i) flexible structure of its molecule; (ii) molecular weight lower than approximately 1,300 g/mol; (iii) nonprotonized character at pH 7.0.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10985475

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  6 in total

1.  Databases and QSAR for cancer research.

Authors:  Adeel Malik; Hemajit Singh; Munazah Andrabi; Syed Akhtar Husain; Shandar Ahmad
Journal:  Cancer Inform       Date:  2007-02-15

Review 2.  Is resistance useless? Multidrug resistance and collateral sensitivity.

Authors:  Matthew D Hall; Misty D Handley; Michael M Gottesman
Journal:  Trends Pharmacol Sci       Date:  2009-09-15       Impact factor: 14.819

3.  Tunicamycin depresses P-glycoprotein glycosylation without an effect on its membrane localization and drug efflux activity in L1210 cells.

Authors:  Mário Sereš; Dana Cholujová; Tatiana Bubenčíkova; Albert Breier; Zdenka Sulová
Journal:  Int J Mol Sci       Date:  2011-11-10       Impact factor: 5.923

4.  3-Aryl-4-nitrobenzothiochromans S,S-dioxide: From Calcium-Channel Modulators Properties to Multidrug-Resistance Reverting Activity.

Authors:  Matteo Micucci; Maurizio Viale; Alberto Chiarini; Domenico Spinelli; Maria Frosini; Cinzia Tavani; Massimo Maccagno; Lara Bianchi; Rosaria Gangemi; Roberta Budriesi
Journal:  Molecules       Date:  2020-02-27       Impact factor: 4.411

5.  Triorganotin Derivatives Induce Cell Death Effects on L1210 Leukemia Cells at Submicromolar Concentrations Independently of P-glycoprotein Expression.

Authors:  Viera Bohacova; Mario Seres; Lucia Pavlikova; Szilvia Kontar; Martin Cagala; Pavel Bobal; Jan Otevrel; Julius Brtko; Zdena Sulova; Albert Breier
Journal:  Molecules       Date:  2018-05-01       Impact factor: 4.411

Review 6.  Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia.

Authors:  Carmelo Gurnari; Simona Pagliuca; Valeria Visconte
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.